299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

10 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05239611 (ClinicalTrials.gov)	February 14, 2022	10/1/2022	Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis	Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis to Improve Patient-centered Outcomes, Including a Novel Measure of Ventilation	Cystic Fibrosis	Drug: Exercise	University of Kansas Medical Center	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
2	NCT04039087 (ClinicalTrials.gov)	September 5, 2019	28/7/2019	Sildenafil Exercise: Role of PDE5 Inhibition	Mechanisms of Exercise Intolerance in Cystic Fibrosis: Role of PDE5 Inhibition	Cystic Fibrosis	Drug: Sildenafil 40mg oral capsule;Drug: Placebo Oral capsule	National Jewish Health	Augusta University;Cystic Fibrosis Foundation	Recruiting	9 Years	N/A	All	40	Phase 2/Phase 3	United States
3	NCT03522831 (ClinicalTrials.gov)	May 1, 2018	19/3/2018	CF Bronchodilation	A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis	Lung Diseases;Cystic Fibrosis	Drug: Salbutamol;Drug: Placebo	University of British Columbia	NULL	Active, not recruiting	19 Years	N/A	All	20	N/A	Canada
4	NCT02875366 (ClinicalTrials.gov)	September 2016	15/8/2016	A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	Cystic Fibrosis	Drug: LUM/IVA;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	N/A	All	70	Phase 4	Australia;United Kingdom
5	EUCTR2016-000066-34-GB (EUCTR)	24/06/2016	25/07/2017	A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation.	Cystic fibrosis in patients homozygous for the F508del-CFTR Mutation MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Orkambi Product Name: lumacaftor /ivacaftor Product Code: VX-809/VX-770 INN or Proposed INN: lumacaftor Other descriptive name: LUMACAFTOR INN or Proposed INN: IVACAFTOR	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Australia;United Kingdom
6	NCT02057458 (ClinicalTrials.gov)	April 2014	4/2/2014	Blood Flow and Vascular Function in Cystic Fibrosis	Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis	Cystic Fibrosis	Drug: Sildenafil (Acute-1 hour);Drug: Sildenafil (Subchronic-4 weeks);Drug: Placebo	Augusta University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	N/A	All	19	Phase 2	United States
7	NCT01937325 (ClinicalTrials.gov)	February 2014	4/9/2013	CPET in CF Patients With One G551D Mutation Taking VX770	Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor)	Cystic Fibrosis	Drug: ivacaftor;Drug: placebo	The Alfred	NULL	Active, not recruiting	16 Years	70 Years	Both	20	Phase 4	Australia
8	NCT01772758 (ClinicalTrials.gov)	August 2011	16/10/2012	Cystic Fibrosis and Endothelial Function: At Rest and During Exercise	Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise	Cystic Fibrosis	Drug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant Cocktail	Augusta University	NULL	Completed	7 Years	N/A	All	64	Phase 2	United States
9	NCT00434278 (ClinicalTrials.gov)	March 2007	11/2/2007	A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease	Cystic Fibrosis	Drug: Dornase alfa;Drug: placebo	Genentech, Inc.	NULL	Terminated	14 Years	N/A	All	27	Phase 4	United States
10	NCT00164021 (ClinicalTrials.gov)	February 2001	13/9/2005	The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation	The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function	Cystic Fibrosis	Procedure: Physiotherapy, exercise, percutaneous gastrostomy feeds;Drug: Anti-reflux pharmacotherapy	Bayside Health	The Alfred;Monash University	Recruiting	16 Years	70 Years	Both	180	N/A	Australia